Perinatal thymic-derived CD8αβ-expressing γδ T cells are innate IFN-γ producers that expand in IL-7R-STAT5B-driven neoplasms.


Journal

Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354

Informations de publication

Date de publication:
27 May 2024
Historique:
received: 13 03 2023
accepted: 25 04 2024
medline: 28 5 2024
pubmed: 28 5 2024
entrez: 27 5 2024
Statut: aheadofprint

Résumé

The contribution of γδ T cells to immune responses is associated with rapid secretion of interferon-γ (IFN-γ). Here, we show a perinatal thymic wave of innate IFN-γ-producing γδ T cells that express CD8αβ heterodimers and expand in preclinical models of infection and cancer. Optimal CD8αβ

Identifiants

pubmed: 38802512
doi: 10.1038/s41590-024-01855-4
pii: 10.1038/s41590-024-01855-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : RCUK | Biotechnology and Biological Sciences Research Council (BBSRC)
ID : BB/R017808/1
Organisme : RCUK | Biotechnology and Biological Sciences Research Council (BBSRC)
ID : BB/R017808/1
Organisme : "la Caixa" Foundation (Caixa Foundation)
ID : HR21-00761
Organisme : EC | EC Seventh Framework Programm | FP7 Ideas: European Research Council (FP7-IDEAS-ERC - Specific Programme: "Ideas" Implementing the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007 to 2013))
ID : ERC-PoC-101069429

Informations de copyright

© 2024. The Author(s).

Références

Ribot, J. C., Lopes, N. & Silva-Santos, B. γδ T cells in tissue physiology and surveillance. Nat. Rev. Immunol. 21, 221–232 (2021).
pubmed: 33057185 doi: 10.1038/s41577-020-00452-4
Silva-Santos, B., Mensurado, S. & Coffelt, S. B. γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat. Rev. Cancer 19, 392–404 (2019).
pubmed: 31209264 pmcid: 7614706 doi: 10.1038/s41568-019-0153-5
Turchinovich, G. & Hayday, A. C. Skint-1 identifies a common molecular mechanism for the development of interferon-gamma-secreting versus interleukin-17-secreting γδ T cells. Immunity 35, 59–68 (2011).
pubmed: 21737317 doi: 10.1016/j.immuni.2011.04.018
Jensen, K. D. et al. Thymic selection determines γδ T cell effector fate: antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma. Immunity 29, 90–100 (2008).
pubmed: 18585064 pmcid: 2601709 doi: 10.1016/j.immuni.2008.04.022
Pereira, P. et al. Critical role of TCR specificity in the development of Vγ1Vδ6.3+ innate NKTγδ cells. J. Immunol. 191, 1716–1723 (2013).
pubmed: 23851687 doi: 10.4049/jimmunol.1203168
Lombes, A. et al. Adaptive immune-like gamma/delta T lymphocytes share many common features with their alpha/beta T cell counterparts. J. Immunol. 195, 1449–1458 (2015).
pubmed: 26123353 doi: 10.4049/jimmunol.1500375
Di Marco Barros, R. et al. Epithelia use butyrophilin-like molecules to shape organ-specific γδ T cell compartments. Cell 167, 203–218 (2016).
pubmed: 27641500 pmcid: 5037318 doi: 10.1016/j.cell.2016.08.030
Hayday, A. C. γδ cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 18, 975–1026 (2000).
pubmed: 10837080 doi: 10.1146/annurev.immunol.18.1.975
Prinz, I., Silva-Santos, B. & Pennington, D. J. Functional development of γδ T cells. Eur. J. Immunol. 43, 1988–1994 (2013).
pubmed: 23928962 doi: 10.1002/eji.201343759
Sumaria, N. et al. Strong TCRγδ signaling prohibits thymic development of IL-17A-secreting γδ T cells. Cell Rep. 19, 2469–2476 (2017).
pubmed: 28636936 pmcid: 5489697 doi: 10.1016/j.celrep.2017.05.071
Munoz-Ruiz, M. et al. TCR signal strength controls thymic differentiation of discrete proinflammatory γδ T cell subsets. Nat. Immunol. 17, 721–727 (2016).
pubmed: 27043412 pmcid: 4875770 doi: 10.1038/ni.3424
Sumaria, N., Martin, S. & Pennington, D. J. Constrained TCRγδ-associated Syk activity engages PI3K to facilitate thymic development of IL-17A-secreting γδ T cells. Sci. Signal. 14, eabc5884 (2021).
pubmed: 34285131 doi: 10.1126/scisignal.abc5884
Lopes, N. et al. Distinct metabolic programs established in the thymus control effector functions of γδ T cell subsets in tumor microenvironments. Nat. Immunol. 22, 179–192 (2021).
pubmed: 33462452 pmcid: 7610600 doi: 10.1038/s41590-020-00848-3
Leclercq, G., De Smedt, M. & Plum, J. Presence of CD8 alpha-CD8 beta-positive TcR gamma/delta thymocytes in the fetal murine thymus and their in vitro expansion with interleukin-7. Eur. J. Immunol. 22, 2189–2193 (1992).
pubmed: 1387610 doi: 10.1002/eji.1830220902
Kadivar, M. et al. CD8αβ
pubmed: 27849165 doi: 10.4049/jimmunol.1601146
Roy Chowdhury, R. et al. NK-like CD8
pubmed: 37000856 doi: 10.1126/sciimmunol.ade3525
Ribot, J. C. et al. γδ-T cells promote IFN-gamma-dependent Plasmodium pathogenesis upon liver-stage infection. Proc. Natl Acad. Sci. USA 116, 9979–9988 (2019).
pubmed: 31028144 pmcid: 6525508 doi: 10.1073/pnas.1814440116
Tough, D. F., Zhang, X. & Sprent, J. An IFN-gamma-dependent pathway controls stimulation of memory phenotype CD8
pubmed: 11342616 doi: 10.4049/jimmunol.166.10.6007
Berg, R. E., Cordes, C. J. & Forman, J. Contribution of CD8
pubmed: 12355433 doi: 10.1002/1521-4141(2002010)32:10<2807::AID-IMMU2807>3.0.CO;2-0
Istaces, N. et al. EOMES interacts with RUNX3 and BRG1 to promote innate memory cell formation through epigenetic reprogramming. Nat. Commun. 10, 3306 (2019).
pubmed: 31341159 pmcid: 6656725 doi: 10.1038/s41467-019-11233-6
Lochner, M. et al. In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10
pubmed: 18504307 pmcid: 2413035 doi: 10.1084/jem.20080034
Ribot, J. C. et al. CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing γδ T cell subsets. Nat. Immunol. 10, 427–436 (2009).
pubmed: 19270712 pmcid: 4167721 doi: 10.1038/ni.1717
Munoz-Ruiz, M. et al. Thymic determinants of γδ T cell differentiation. Trends Immunol. 38, 336–344 (2017).
pubmed: 28285814 doi: 10.1016/j.it.2017.01.007
Coffey, F. et al. The TCR ligand-inducible expression of CD73 marks γδ lineage commitment and a metastable intermediate in effector specification. J. Exp. Med. 211, 329–343 (2014).
pubmed: 24493796 pmcid: 3920555 doi: 10.1084/jem.20131540
Pennington, D. J. et al. The inter-relatedness and interdependence of mouse T cell receptor γδ
pubmed: 14502287 doi: 10.1038/ni979
Prieto, J. M. B. & Felippe, M. J. B. Development, phenotype, and function of non-conventional B cells. Comp. Immunol. Microbiol. Infect. Dis. 54, 38–44 (2017).
pubmed: 28916000 doi: 10.1016/j.cimid.2017.08.002
Gordon, S. M. et al. Requirements for eomesodermin and promyelocytic leukemia zinc finger in the development of innate-like CD8
pubmed: 21383242 doi: 10.4049/jimmunol.1100037
Zenatti, P. P. et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat. Genet. 43, 932–939 (2011).
pubmed: 21892159 pmcid: 7424552 doi: 10.1038/ng.924
Silva, A. et al. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res. 71, 4780–4789 (2011).
pubmed: 21593192 doi: 10.1158/0008-5472.CAN-10-3606
Barata, J. T., Durum, S. K. & Seddon, B. Flip the coin: IL-7 and IL-7R in health and disease. Nat. Immunol. 20, 1584–1593 (2019).
pubmed: 31745336 doi: 10.1038/s41590-019-0479-x
Bandapalli, O. R. et al. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica 99, e188–e192 (2014).
pubmed: 24972766 pmcid: 4181267 doi: 10.3324/haematol.2014.104992
Pham, H. T. T. et al. STAT5B
pubmed: 29200404 doi: 10.1172/JCI94509
de Araujo, E. D. et al. Structural and functional consequences of the STAT5B
pubmed: 31175292 pmcid: 6555848 doi: 10.1038/s41467-019-10422-7
Nicolae, A. et al. Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas. Leukemia 28, 2244–2248 (2014).
pubmed: 24947020 pmcid: 7701980 doi: 10.1038/leu.2014.200
Silva, A. et al. Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood 138, 1040–1052 (2021).
pubmed: 33970999 pmcid: 8462360 doi: 10.1182/blood.2019000553
Malard, F. & Mohty, M. Acute lymphoblastic leukaemia. Lancet 395, 1146–1162 (2020).
pubmed: 32247396 doi: 10.1016/S0140-6736(19)33018-1
Freeman, B. E. et al. Regulation of innate CD8
pubmed: 22665806 pmcid: 3382521 doi: 10.1073/pnas.1203543109
Nunes-Cabaco, H. et al. Human CD4 T cells from thymus and cord blood are convertible into CD8 T cells by IL-4. Front. Immunol. 13, 834033 (2022).
pubmed: 35222424 pmcid: 8880616 doi: 10.3389/fimmu.2022.834033
Barbarin, A. et al. Phenotype of NK-Like CD8
pubmed: 28396661 pmcid: 5366313 doi: 10.3389/fimmu.2017.00316
Broussard, C. et al. Altered development of CD8
pubmed: 16860760 doi: 10.1016/j.immuni.2006.05.011
Nayar, R. et al. TCR signaling via Tec kinase ITK and interferon regulatory factor 4 (IRF4) regulates CD8
pubmed: 23011795 pmcid: 3478592 doi: 10.1073/pnas.1205742109
Khairallah, C., Dechanet-Merville, J. & Capone, M. γδ T cell-mediated immunity to cytomegalovirus infection. Front. Immunol. 8, 105 (2017).
pubmed: 28232834 pmcid: 5298998 doi: 10.3389/fimmu.2017.00105
Sanchez Sanchez, G. et al. Identification of distinct functional thymic programming of fetal and pediatric human γδ thymocytes via single-cell analysis. Nat. Commun. 13, 5842 (2022).
pubmed: 36195611 pmcid: 9532436 doi: 10.1038/s41467-022-33488-2
Gibbons, D. L. et al. Neonates harbour highly active γδ T cells with selective impairments in preterm infants. Eur. J. Immunol. 39, 1794–1806 (2009).
pubmed: 19544311 doi: 10.1002/eji.200939222
Ma, L. et al. Effector Vγ9Vδ2 T cell response to congenital Toxoplasma gondii infection. JCI Insight 6, e138066 (2021).
pubmed: 34255746 pmcid: 8409983 doi: 10.1172/jci.insight.138066
Vermijlen, D. et al. Human cytomegalovirus elicits fetal γδ T cell responses in utero. J. Exp. Med. 207, 807–821 (2010).
pubmed: 20368575 pmcid: 2856038 doi: 10.1084/jem.20090348
Gaballa, A. et al. CD8
pubmed: 31885619 pmcid: 6925825 doi: 10.1155/2019/6348060
Maki, K., Sunaga, S. & Ikuta, K. The V-J recombination of T cell receptor-gamma genes is blocked in interleukin-7 receptor-deficient mice. J. Exp. Med. 184, 2423–2427 (1996).
pubmed: 8976198 pmcid: 2196379 doi: 10.1084/jem.184.6.2423
Lamy, T., Moignet, A. & Loughran, T. P. Jr. LGL leukemia: from pathogenesis to treatment. Blood 129, 1082–1094 (2017).
pubmed: 28115367 doi: 10.1182/blood-2016-08-692590
Teramo, A. et al. Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation. Nat. Commun. 13, 3298 (2022).
pubmed: 35676278 pmcid: 9177852 doi: 10.1038/s41467-022-31015-x
Okkenhaug, K. et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297, 1031–1034 (2002).
pubmed: 12130661 doi: 10.1126/science.1073560
Stark, A. K. et al. PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner. Nat. Commun. 9, 3174 (2018).
pubmed: 30093657 pmcid: 6085315 doi: 10.1038/s41467-018-05674-8
Philpott, K. L. et al. Lymphoid development in mice congenitally lacking T cell receptor alpha beta-expressing cells. Science 256, 1448–1452 (1992).
pubmed: 1604321 doi: 10.1126/science.1604321
Courtois, L. et al. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition. Blood 142, 158–171 (2023).
pubmed: 37023368
Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).
pubmed: 30944313 pmcid: 6447622 doi: 10.1038/s41467-019-09234-6
Pui, C. H. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730–2741 (2009).
pubmed: 19553647 pmcid: 2754320 doi: 10.1056/NEJMoa0900386
Jeha, S. et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16. J. Clin. Oncol. 37, 3377–3391 (2019).
pubmed: 31657981 pmcid: 7351342 doi: 10.1200/JCO.19.01692

Auteurs

Nital Sumaria (N)

Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK.

Gina J Fiala (GJ)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. gina.fiala@biologie.uni-freiburg.de.
Faculty of Biology, University of Freiburg, Freiburg, Germany. gina.fiala@biologie.uni-freiburg.de.
Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany. gina.fiala@biologie.uni-freiburg.de.

Daniel Inácio (D)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Marta Curado-Avelar (M)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Ana Cachucho (A)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Rúben Pinheiro (R)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Robert Wiesheu (R)

Cancer Research UK Scotland Institute, Glasgow, UK.
School of Cancer Sciences, University of Glasgow, Glasgow, UK.

Shunsuke Kimura (S)

St. Jude's Children's Research Hospital, Memphis, TN, USA.

Lucien Courtois (L)

Hôpital Necker Enfants-Malades, Université de Paris, Paris, France.

Birte Blankenhaus (B)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Julie Darrigues (J)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Tobias Suske (T)

Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.

Afonso R M Almeida (ARM)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Susana Minguet (S)

Faculty of Biology, University of Freiburg, Freiburg, Germany.
Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.
Center of Chronic Immunodeficiency CCI, University Clinics and Medical Faculty, Freiburg, Germany.

Vahid Asnafi (V)

Hôpital Necker Enfants-Malades, Université de Paris, Paris, France.

Ludovic Lhermitte (L)

Hôpital Necker Enfants-Malades, Université de Paris, Paris, France.

Charles G Mullighan (CG)

St. Jude's Children's Research Hospital, Memphis, TN, USA.

Seth B Coffelt (SB)

Cancer Research UK Scotland Institute, Glasgow, UK.
School of Cancer Sciences, University of Glasgow, Glasgow, UK.

Richard Moriggl (R)

Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.

João T Barata (JT)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Daniel J Pennington (DJ)

Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK. d.pennington@qmul.ac.uk.

Bruno Silva-Santos (B)

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

Classifications MeSH